In a strategic move to fortify its healthcare infrastructure and mitigate medical supply vulnerabilities, Sri Lanka is actively seeking an expanded bilateral partnership with India in pharmaceutical manufacturing and healthcare services. The initiative aims to leverage India’s position as a global pharmaceutical powerhouse to build a more self-reliant healthcare ecosystem in Sri Lanka.
Key Highlights
- Sri Lanka aims to attract Indian investments and technology transfer to expand domestic medicine production.
- Focus on developing dedicated pharmaceutical manufacturing zones and fostering strategic joint ventures.
- The collaboration seeks to stabilize local supply chains and enhance affordable access to essential medicines.
Sri Lanka currently relies heavily on foreign imports to fulfill its national pharmaceutical requirements, with a substantial share historically sourced from Indian suppliers. By transitioning from direct procurement to collaborative manufacturing, Sri Lanka aims to lower healthcare costs, create skilled local jobs, and build long-term economic resilience.
The prospective partnership is expected to cover technical cooperation, capacity building, and investment in active pharmaceutical ingredient (API) production facilities. As discussions progress, both nations stand to reinforce strategic and economic ties through mutual commitments to regional health security.